|
Federal
Register Notices > Notice of
Application 2006 >
Orasure Technologies, Inc.
FR Doc E6-12459 [Federal Register: August 2, 2006 (Volume 71, Number 148)]
[Notices] [Page 43814] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02au06-113]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations
(CFR), this is notice that on February 19, 2006, Orasure Technologies, Inc.,
Lehigh University, Seeley G. Mudd-Building 6, Bethlehem, Pennsylvania 18015,
made application by renewal, and by letter, to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the basic
classes of controlled substances listed in Schedule I and II:
|
Drug
|
Schedule
|
|
Lysergic acid diethylamide (LSD) (7315)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Normorphine (9313)
|
I
|
|
Tetrahydrocannabinols (THC) (7370)
|
I
|
|
Alphamethadol (9605)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Cocaine (9041)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Morphine (9300)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Oxymorphone (9652)
|
II
|
The company plans to manufacture the listed controlled substances in bulk to
manufacture controlled substance derivatives. These derivatives will be used in
diagnostic products created specifically for internal use only.
Any other such applicant and any person who is presently registered with DEA
to manufacture such a substance may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR Sec. 1301.33(a).
Any such written comments or objections being sent via regular mail may be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC. 20537,
Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL);
or any being sent via express mail should be sent to DEA Headquarters,
Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis
Highway, Alexandria, Virginia 22301; and must be filed no later than October 2,
2006.
Dated: July 26, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E6-12459
Filed 8-1-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
